共 95 条
[1]
Kappelman MD(2008)Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults Gastroenterology. 135 1907-1913
[2]
Rifas-Shiman SL(2002)Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 1541-1549
[3]
Porter CQ(2004)Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 876-885
[4]
Hanauer SB(1997)A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group N Engl J Med 337 1029-1035
[5]
Feagan BG(2007)Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology. 132 52-65
[6]
Lichtenstein GR(2008)Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study Gastroenterology. 135 1493-1499
[7]
Sands BE(2007)Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial Ann Intern Med 146 829-838
[8]
Anderson FH(2007)Maintenance therapy with certolizumab pegol for Crohn's disease N Engl J Med 357 239-250
[9]
Bernstein CN(2005)Natalizumab induction and maintenance therapy for Crohn's disease N Engl J Med 353 1912-1925
[10]
Targan SR(2005)Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2462-2476